Name: BIOTRICITY INC (BTCY) Stock
Brand: BIOTRICITY INC
Rating: 2 (3 reviews)

BTCY Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Zacks Investment Research - Mentions: VEEV

Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates

9 days ago - By: Biotricity Inc.

Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026

10 days ago - By: Zacks Investment Research - Mentions: FATE

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

11 days ago - By: Zacks Investment Research - Mentions: LUNG

Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates

16 days ago - By: Biotricity Inc.

Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th

16 days ago - By: Zacks Investment Research - Mentions: FLGT

Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates

a year ago - By: biotricity

Biotricity Achieves Positive Free Cash Flow Milestone

17 days ago - By: Zacks Investment Research - Mentions: DOCS

Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates

3 months ago - By: Health-E Commerce

Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users

3 months ago - By: Biotricity Inc.

Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform

3 months ago - By: Zacks Investment Research - Mentions: BWAY

Are Medical Stocks Lagging Biotricity (BTCY) This Year?

3 months ago - By: Zacks Investment Research

Biotricity (BTCY) Upgraded to Buy: Here's Why

3 months ago - By: Biotricity Inc.

Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

a year ago - By: InvestorPlace

BTCY Stock Earnings: Biotricity Reported Results for Q1 2025

3 months ago - By: Biotricity Inc.

Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

4 months ago - By: Biotricity Inc.

Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

4 months ago - By: Biotricity Inc.

Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

5 months ago - By: Yahoo Finance

Rogue Funds’ New Holding: Biotricity (BTCY)

8 months ago - By: Biotricity Inc.

Biotricity Recognized by Financial Times as One of 2025’s Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

a year ago - By: BusinessInsider

BTCY Stock Earnings: Biotricity Beats EPS, Misses Revenue for Q4 2024

9 months ago - By: Biotricity Inc.

Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

9 months ago - By: Biotricity Inc.

Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025

9 months ago - By: Biotricity Inc.

Biotricity Announces Cashflow Breakeven with Biggest Quarter in History and a Revenue Increase of 11%

10 months ago - By: biotricity

Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform

a year ago - By: biotricity

Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand

a year ago - By: Biotricity Inc.

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025

a year ago - By: Biotricity Inc.

BIOTRICITY INC (BTCY) Stock News

BTCY Latest News, Press Relases and Analysis

Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates

Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026

Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates

Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th

Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates

Biotricity Achieves Positive Free Cash Flow Milestone

Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates

Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users

Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform

Are Medical Stocks Lagging Biotricity (BTCY) This Year?

Biotricity (BTCY) Upgraded to Buy: Here's Why

Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

BTCY Stock Earnings: Biotricity Reported Results for Q1 2025

Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

Rogue Funds’ New Holding: Biotricity (BTCY)

Biotricity Recognized by Financial Times as One of 2025’s Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

BTCY Stock Earnings: Biotricity Beats EPS, Misses Revenue for Q4 2024

Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025

Biotricity Announces Cashflow Breakeven with Biggest Quarter in History and a Revenue Increase of 11%

Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform

Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025

Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th